Exhibit 99.1
| Press Release |  |
| www.shire.com |
Director/PDMR Shareholding
March 28, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by person discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”) | ||
| a) | Name | Philip Vickers | |
| 2. | Reason for the notification | ||
| a) | Position / status | Head of Research and Development – PDMR | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Disposal of ADSs | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $177.59 | 100 | ||
| $177.59 | 100 | ||
| $177.58 | 100 | ||
| $177.58 | 100 | ||
| $177.57 | 100 | ||
| $177.56 | 100 | ||
| $177.55 | 100 | ||
| $177.51 | 10 | ||
| $177.49 | 100 | ||
| $177.47 | 100 | ||
| $177.47 | 100 | ||
| $177.48 | 100 | ||
| $177.44 | 204 | ||
| $177.44 | 96 |
| d) | Aggregated information - Aggregated volume - Price | Weighted average price | Volume |
| $177.52 | 1,410
| ||
| e) | Date of the transaction | March 27, 2017 | |
| f) | Place of the transaction | NASDAQ | |
| 5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Disposal of ADSs | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $177.50 | 200 | ||
| $177.44 | 400 | ||
| $177.45 | 200 | ||
| $177.44 | 1 | ||
| $177.45 | 600 | ||
| $177.45 | 300 | ||
d)
| Aggregated information - Aggregated volume - Price | Weighted average price | Volume |
| $177.45 | 1,701
| ||
| e) | Date of the transaction | March 27, 2017 | |
| f) | Place of the transaction | NYSE BEST | |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | ikarp@shire.com | +1 781 482 9018 |
| Robert Coates | rcoates@shire.com | +44 1256 894874 |
| Media | ||
| Lisa Adler | lisa.adler@shire.com | +1 617 588 8607 |
| Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com